Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2017

View Archived Issues

EMA grants SPK-9001 access to PRIME program for hemophilia B

Melinta and Menarini sign development and commercialization agreement for delafloxacin

EMA grants orphan drug designation to Resolaris for limb girdle muscular dystrophy

Theratechnologies acquires commercial rights to ibalizumab in E.U. and other countries

C5aR1 as a potential new therapeutic target in Gaucher disease

FDA approves Noctiva for nocturnal polyuria

Chemotherapy-induced pyrimidine synthesis provides a target for triple-negative breast cancer

Santen Pharmaceutical and Singapore Eye Research Institute launch 5-year ophthalmic collaboration

PRC2 and BET bromodomain proteins as therapeutic targets for diffuse intrinsic pontine gliomas

Amryt completes phase III discussions with FDA and EMA for AP-101 in epidermolysis bullosa

Phase I study of Lymfactin advances to highest dose level

Cabozantinib S-malate from Exelixis granted U.S. orphan drug designation for the treatment of HCC

Vernalis and Servier establish new 2-year oncology drug discovery collaboration

TiGenix updates progress of European MAA procedure for Cx-601

Genetic analyses of phase II studies of Qbeco in Crohn's disease and ulcerative colitis

FORUM Pharmaceuticals discloses novel CHRNA7 agonists

Incyte identifies new TAM kinase inhibitors

U.S. Dept. of Health & Human Services patents thioredoxin reductase inhibitors

Memorial Sloan-Kettering presents novel Mcl-1 inhibitors

Zafgen discovers methionine aminopeptidase 2 inhibitors

The Broad Institute patents anti-mycobacterial compounds

Angsana to provide Asian diagnostic screening for STARTRK-2 trial of entrectinib

Phase I results presented for ANB-020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...